Platelet inhibition limits TGF-β overexpression and matrix expansion after induction of anti-thy1 glomerulonephritis

Kidney International

Volumn 65, Issue 6, 2004, Pages 2238-2248

  Peters, Harm ^a   Eisenberg, Ralph ^a   Daig, Ute ^a   Liefeldt, Lutz ^a   Westenfeld, Ralf ^a   Gaedeke, Jens ^a   Krämer, Stephanie ^a   Neumayer, Hans H ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

ACE inhibition; Fibrosis; Platelets; TGF 1

Indexed keywords

CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; FIBRONECTIN; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; DRUG EFFECT; GENE EXPRESSION; GLOMERULONEPHRITIS; MACROPHAGE; MALE; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 2442676339     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00630.x     Document Type: Article

References (38)

1. BORDER WA, NOBLE NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 331:1286-1292, 1994
2. BRANTON MH, KOPP JB: TGF-beta and fibrosis. Microbes Infect 1:1349-1365, 1999
3. KLAHR S, SCHREINER G, ICHIKAWA I: The progression of renal disease. N Engl J Med 318:1657-1666, 1988
4. NOBLE NA, BORDER WA: Angiotensin II in renal fibrosis: Should TGF-beta rather than blood pressure be the therapeutic target? Semin Nephrol 17:455-466, 1997
5. PETERS H, BORDER WA, NOBLE NA: From rats to men: A perspective on dietary L-arginine supplementation in human renal disease. Nephrol Dial Transplant 14:1640-1650, 1999
6. BORDER WA, OKUDA S, LANGUINO LR, et al: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta1. Nature 346:371-374, 1990
7. ZIYADEH FN, HOFFMAN BB, HAN DC, et al: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015-8020, 2000
8. EDDY AA: Molecular basis of renal fibrosis. Pediatr Nephrol 15:290-301, 2000
9. PANZER U, STAHL RAK: Chemokines and renal inflammation. Nephrology 20:335-341, 1999
10. ROSS R: Atherosclerosis - An inflammatory disease. N Engl J Med 340:315-126, 1999
11. RUGGERI ZM: Platelets in atherothrombosis. Nat Med 8:1227-1234, 2002
12. HOLLOPETER G, JANTZEN HM, VINCENT D, et al: Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409:202-207, 2001
13. FOSTER CJ, PROSSER DM, AGANS JM, et al: Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 107:1591-1598, 2001
14. SHARIS PJ, CANNON CP, LOSCALZO J: The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 129:394-405, 1998
15. ZOJA C, REMUZZI G: Role of platelets in progressive glomerular diseases. Pediatr Nephrol 9:495-502, 1995
16. PETERS H, NOBLE NA, BORDER WA: Targeting TGF-beta overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 54:1575-1583, 1998
17. NARITA I, BORDER WA, KETTELER M, NOBLE NA: Nitric oxide mediates immunologic injury to kidney mesangium in experimental glomerulonephritis. Lab Invest 72:17-24, 1995
18. HERBERT JM, FREHEL D, BERNAT A, et al: Clopidogrel hydrogensulfate. Drugs Future 18:107-112, 1993
19. PETERS H, BORDER WA, NOBLE NA: L-arginine supplementation increases mesangial cell injury and subsequent tissue fibrosis in experimental glomerulonephritis. Kidney Int 55:2264-2273, 1999
20. JOHNSON RJ, GARCIA RL, PRITZL P, ALPERS CE: Platelets mediate glomerular cell proliferation in immune complex nephritis induced by anti-mesangial cell antibodies in the rat. Am J Pathol 136:369-374, 1990
21. WENZEL UO, WOLF G, THAISS F, et al: Renovascular hypertension does not influence repair of glomerular lesions induced by anti-thymocyte glomerulonephritis. Kidney Int 58:1135-1147, 2000
22. DEJANA E, VILLA S, DE GAETANO G: Bleeding time in rats: A comparison of different experimental conditions. Thromb Haemost 48:108-111, 1982
23. PETERS H, RÜCKERT M, GAEDEKE J, et al: ACE inhibition but not β-adrenergic blockade limits TGF-β overexpression in acute normotensive anti-thy1 glomerulonephritis. J Hypertens 21:771-780, 2003
24. PETERS H, BORDER WA, NOBLE NA: Tandem antifibrotic actions of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis. Kidney Int 57:922-1001, 2000
25. GREEN LC, WAGNER DA, GLOGOWSKI J, et al: Analysis of nitrate, nitrite and 15N-nitrate in biological fluids. Anal Biochem 126:131-138, 1982
26. RUETTEN H, ZABEL U, LINZ W, SCHMIDT HH: Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. Circ Res 85:534-541, 1999
27. WINCHESTER JF: Therapeutic uses of aspirin in renal diseases. Am J Kidney Dis 28:S20-S23, 1996
28. MASUDA Y, SHIMIZU A, MORI T, et al: Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol 159:599-608, 2001
29. WADA Y, MORIOKA T, OYANAGI-TANAKA Y, et al: Impairment of vascular regeneration precedes progressive glomerulosclerosis in anti-thy 1 glomerulonephritis. Kidney Int 61:432-443, 2002
30. BHATT DL, MARSO SP, HIRSCH AT, et al: Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 90:625-628, 2002
31. CANNON CP: Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis. Am J Cardiol 90:760-762, 2002
32. FLOEGE J, ENG E, YOUNG BA, et al: Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis. Kidney Int 43:369-380, 1993
33. ZOJA C, PERICO N, BERGAMELLI A, et al: Ticlopidine prevents renal disease progression in rats with reduced renal mass. Kidney Int 37:934-942, 1990
34. PETERS H, BORDER WA, NOBLE NA: Angiotensin II blockade and low protein diet produce additive therapeutic effects on experimental glomerulonephritis. Kidney Int 57:1493-1501, 1999
35. KINCAID-SMITH P: Coagulation and renal disease. Kidney Int 2:183-190, 1972
36. HERLITZ H, SVALANDER C, TARKOWSKI A, WESTBERG G: Effect of captopril on murine systemic lupus erythematosus disease. J Hypertens (Suppl 6):S684-S686, 1988
37. RUIZ-ORTEGA M, LORENZO O, SUZUKI Y, et al: Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 10:321-329, 2001
38. WOLF G, WENZEL U, BURNS KD, et al: Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors. Kidney Int 61:1986-1995, 2002